|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of murine systemic lupus erythematosus in the absence of BAFF.
|
31493335 |
2020 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, G-MDSCs may contribute to the IFN signature in SLE B cells through the NEAT1-BAFF axis, highlighting G-MDSCs as a potential therapeutic target to treat SLE.
|
31513833 |
2020 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the expression of the cytokines BAFF and APRIL and their association with the receptors BAFF-R and TACI on CD3+ T cells and to evaluate Th1/Th2/Th17 cytokine profile in patients with SLE.
|
30467093 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 2011, the anti-BAFF monoclonal antibody, belimumab, became the first FDA-approved drug for SLE in 50+ years.
|
31657965 |
2019 |
|
TNFSF13B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in expression coincided with changes in SLE disease activity.
|
30626389 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with murine ICOSL/BAFF bispecific or combination therapy was more efficacious than single ICOSL or BAFF inhibitor in mouse NZB/NZW lupus model.
|
30789152 |
2019 |
|
TNFSF13B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The increased miR-152-3p expression in SLE B-cells led to an increase in BAFF expression by inhibiting KLF5 expression.
|
31178864 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
High BAFF expression is related to active disease, renal and hematological involvement; therefore, it could be considered as follow-up biomarker in SLE patients.
|
30747361 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum BAFF was also increased in SLE, but this association was attenuated after adjusting for age and ethnicity.
|
31024730 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
This includes increased B cell-activating factor (BAFF), the only current biologic target in systemic lupus erythematosus (SLE); IFN-κ, a key inflammatory mediator in cutaneous lupus; and CXCL13, a biomarker of early-onset SLE and renal involvement.
|
30996136 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Variations of the 5, 10- methylenetetrahydrofolate reductase (MTHFR) gene -the main genetic determinant of hyperhomocystenemia in humans-as well the interferon regulatory factor-8 (IRF8), FcγRIIA and BAFF genes have been all linked to subclinical atherosclerosis in SLE.
|
31444033 |
2019 |
|
TNFSF13B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with systemic lupus erythematosus (SLE) have high levels of both BAFF and immature B cells.
|
31423896 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The administration of belimumab, a monoclonal antibody specific for BAFF and approved for lupus therapy, could potentiate the efficacy of rituximab and enable longer periods of disease remission.
|
31848169 |
2019 |
|
TNFSF13B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased serum concentrations of BAFF are related to lupus nephritis and disease activity among SLE patients.
|
31752784 |
2019 |
|
TNFSF13B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest the inhibitory effects of GYF-21 on the survival, activation, proliferation, and differentiation of B cells mainly via blocking BAFF activated signaling pathways, and its potential to be developed into therapeutic drug for autoimmune diseases, especially systemic lupus erythematosus (SLE).
|
30597293 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Arguably, the success of B cell depletion with rituximab in open-label clinical trials, the approval of belimumab (which blocks B cell-activating factor (BAFF)) for use in patients with lupus nephritis in the USA and in difficult-to-treat patients with SLE in the UK and the recognition that clinical trial design can be improved have given some cause for hope.
|
31165780 |
2019 |
|
TNFSF13B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, in 35 patients with drug-naïve SLE (n = 35), we investigated correlation between NETs-associated markers [DNase I concentration, myeloperoxidase (MPO) activity, anti-MPO antibodies, cell-free DNA (cfDNA), NETolytic activity] with serological parameters [anti-dsDNA antibodies, C3, C4 and B-cell activating factor (BAFF) levels] and disease activity measured by modified SLE Disease Activity Index (M-SLEDAI-2K).
|
31444555 |
2019 |
|
TNFSF13B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
B cell alterations during BAFF inhibition with belimumab in SLE.
|
30593436 |
2019 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-BAFF SLE group displayed increased rates of both plaque formation and arterial wall thickening (defined as IMT>0.90 mm) compared to patients with low BAFF levels (58.1% vs 43.6%, p:0.048 and 38.6% vs 23.2%, p-value: 0.024, respectively).
|
29859654 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these findings highlight how multiple signaling pathways integrate to promote class-switched autoAb production by transitional B cells, events that likely impact the pathogenesis of SLE and other BAFF-dependent autoimmune diseases.
|
30373855 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The B cell survival factor (TNFSF13B/BAFF) is often elevated in autoimmune diseases and is targeted in the clinic for the treatment of systemic lupus erythematosus.
|
29572442 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since lupus nephritis is the main cause of morbidity and mortality for SLE patients, the aim of this study was to investigate whether renal tubular epithelial cells (TEC) are an important source of BAFF and thus may contribute to the pathogenesis and progression of SLE.
|
28659046 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, TNFSF13B BAFF-var was significantly associated with SLE in the Spanish (p = 0.001, OR = 1.41, 95% CI = 1.14-1.74) and the German cohorts (p = 0.030, OR = 1.86, 95% CI = 1.05-3.28), with a statistically significant p-value obtained in the meta-analysis (p = 0.0002, OR = 1.46, 95% CI = 1.09-2.32).
|
29844438 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeted inhibitors of B-cell activating factor (BAFF) have been evaluated in phase III trials in over 4000 patients with systemic lupus erythematosus (SLE).
|
29563108 |
2018 |
|
TNFSF13B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Belimumab is a fully humanized monoclonal antibody that targets soluble B lymphocyte stimulator (BLyS), approved for treatment of serologically active SLE in addition to standard of care.
|
30342482 |
2018 |